Omburtamab Biosimilar - Research Grade

Human

CD276

>1mg/ml

Mouse IgG1 Kappa

Anti-Mouse CD276 (MJ18) In Vivo Antibody - Low Endotoxin (ICH1208), 8H9 Biosimilar - Research Grade (ICH5118), Enoblituzumab Biosimilar - Research Grade (ICH5124), Ifinatamab Biosimilar - Research Grade (ICH5204), Mirzotamab Biosimilar - Research Grade (ICH5687), Vobramitamab Biosimilar - Research Grade (ICH5985)

https://www.imgt.org/mAb-DB/

ICH3002

Q5ZPR3

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of the anti-B7-H3 (CD276) antibody omburtamab, supplied for research use only. It is built around the same molecular target as the originator drug but is not the clinical agent and is not intended for human or veterinary use. Provided as a purified mouse IgG1 kappa recombinant protein, it is well suited to in-vitro and preclinical benchtop work: characterizing B7-H3 expression on tumor and stromal cells, serving as a binding or blocking reagent, acting as a positive control or capture antibody in assays, and functioning as a starting scaffold for antibody-drug-conjugate (ADC), radioimmunoconjugate, or bispecific development. It is offered in low-endotoxin research grade (<1 EU/mg) and ultra-low-endotoxin (<0.5 EU/mg) formats, and can be supplied in bulk milligram-to-gram quantities to support scale-up, assay standardization, and reproducibility across studies. Because it is unconjugated, users retain flexibility to add their own labels, payloads, or reporters. CD276, better known as B7-H3, is a type I transmembrane glycoprotein of the B7/CD28 immunoglobulin superfamily. Human B7-H3 predominantly exists as a 4Ig isoform, with two tandem pairs of IgV-IgC extracellular domains. It shows limited expression on normal tissues but is markedly overexpressed on many solid tumors, including neuroblastoma, and on tumor-associated vasculature, which underlies its appeal as a targeting antigen. B7-H3 acts as an immune checkpoint-type molecule with context-dependent, mostly inhibitory effects on T-cell activation and cytokine production, and has additional reported non-immunological roles in tumor proliferation, migration, and metabolism. Its counter-receptor(s) remain incompletely defined. This combination of tumor-restricted surface expression and immunoregulatory function makes it an actively studied target for antibody, ADC, and cell-therapy approaches.

B7-H3, B7H3

Detects human CD276

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Q: Is the Omburtamab biosimilar available in gram quantities?

A: Yes — it is supplied in scalable milligram to gram quantities for heavy-usage and high-throughput laboratories.

Q: Is this research-grade Omburtamab biosimilar suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Omburtamab biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Omburtamab that binds human CD276.